Clinical efficacy and safety for leflunomide and dehydrocortisone in the treatment of immunoglobulin A nephropathy
10.13699/j.cnki.1001-6821.2016.01.002
- VernacularTitle:来氟米特与泼尼松对免疫球蛋白A肾病的临床疗效与安全性研究
- Author:
Shi-Zhong SHEN
1
;
Zhong-Min YANG
;
Jia-Ying CAI
;
Qian-Hong XIE
;
Yi-Yang HU
;
Ling-Yun SUN
;
Zong-Pei JIANG
Author Information
1. 福建医科大学 附属泉州第一医院 肾内科
- Keywords:
immunoglobulin A nephropathy;
leflunomide;
dehydrocorti-sone;
albuminuria
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(1):6-8
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety be-tween leflunomide and dehydrocortisone in the treatment of immunoglobu-lin A ( IgA) nephropathy.Methods Sixty IgA nephropathy patients were divided into control group (n=32) and experiment group(n=28). Patients in control group were administered metacortandracin 0.5 mg· kg-1 until 2 months.And then with 5 mg decrease every 2 weeks. Patients in experiment group were administered leflunomide 20 mg, twice a day for 3 days and than 20 mg, once a day for 3 months.The 24 h urine protein, glomerular filtration rate, albumin, clinical efficacy and safety were compared between the two groups .Results After treatment, the effective rate were 53.13% and 64.29% in control and experiment group, with no statistical difference (P>0.05).The 24 h urine protein was significantly decreased ( P<0.05 ) , glomerular filtration rate and al-bumin significantly increased in two groups after treatment ( P<0.05 ) , but there was no statistical difference between the two group ( P>0.05 ) . The incidence rate of adverse drug reaction in experiment group and con-trol group were 21 .43% and 15.63%, without significant difference (P>0.05).Conclusion Leflunomide was effective and safe in the treatment of IgA nephropathy , without difference with dehydrocortisone .
